ID   ML-2
AC   CVCL_1418
SY   ML2
DR   BTO; BTO:0001885
DR   CLO; CLO_0007736
DR   EFO; EFO_0002238
DR   CLDB; cl3490
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03472168
DR   cancercelllines; CVCL_1418
DR   Cell_Model_Passport; SIDM00441
DR   ChEMBL-Cells; CHEMBL3307604
DR   ChEMBL-Targets; CHEMBL614356
DR   Cosmic; 787454
DR   Cosmic; 850389
DR   Cosmic; 908141
DR   Cosmic; 975271
DR   Cosmic; 999728
DR   Cosmic; 1012092
DR   Cosmic; 1078727
DR   Cosmic; 1078739
DR   Cosmic; 1151785
DR   Cosmic; 1181602
DR   Cosmic; 1281329
DR   Cosmic; 1524834
DR   Cosmic; 2131545
DR   Cosmic; 2391904
DR   Cosmic; 2750863
DR   Cosmic-CLP; 908141
DR   DepMap; ACH-002273
DR   DSMZ; ACC-15
DR   DSMZCellDive; ACC-15
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   EGA; EGAS00001002554
DR   GDSC; 908141
DR   GEO; GSM236791
DR   GEO; GSM236827
DR   GEO; GSM482497
DR   GEO; GSM1374683
DR   GEO; GSM1446737
DR   GEO; GSM1670116
DR   IGRhCellID; ML2
DR   LINCS_LDP; LCL-1060
DR   PharmacoDB; ML2_942_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1418
DR   PubChem_Cell_line; CVCL_1418
DR   Wikidata; Q54905843
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=2985879;
RX   PubMed=3159941;
RX   PubMed=3458526;
RX   PubMed=3874327;
RX   PubMed=6091813;
RX   PubMed=14671638;
RX   PubMed=15843827;
RX   PubMed=16408098;
RX   PubMed=16969076;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Doubling time: ~60 hours (DSMZ=ACC-15).
CC   HLA typing: A*02:01,02:01; B*44:02,51:01; C*05:01,14:02; DRB1*14:103,14:103 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene fusion; HGNC; 7137; AFDN + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFDN, MLL-MLLT4, MLL-AF6 (PubMed=14671638; PubMed=25485619).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala146Thr (c.436G>A); ClinVar=VCV000197243; Zygosity=Heterozygous (PubMed=16969076; Cosmic-CLP=908141; DepMap=ACH-002273).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=0%; East Asian, South=0%; South Asian=0.26%; European, North=70.54%; European, South=29.2% (PubMed=30894373).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): Cosmic-CLP=908141; DSMZ=ACC-15; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 9,12
ST   D16S539: 9,12
ST   D18S51: 15,18
ST   D19S433: 14
ST   D21S11: 29
ST   D2S1338: 16,17
ST   D3S1358: 15
ST   D5S818: 12
ST   D7S820: 9,11
ST   D8S1179: 8,13
ST   FGA: 23,25
ST   Penta D: 12
ST   Penta E: 5,7
ST   TH01: 7,9.3
ST   TPOX: 8,10
ST   vWA: 16
DI   NCIt; C9154; Adult acute myeloid leukemia
DI   NCIt; C132105; Acute myeloid leukemia with t(6;11)(q27;q23) KMT2A-MLLT4
DI   ORDO; Orphanet_519; Acute myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_0436 ! ML-1 [Human leukemia]
OI   CVCL_H526 ! ML-3
SX   Male
AG   26Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 42
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- 1.
RT   carboxylic esterase.";
RL   Leuk. Res. 9:209-229(1985).
//
RX   PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- III.
RT   Beta-hexosaminidase (E.C. 3.2.1.30).";
RL   Leuk. Res. 9:549-559(1985).
//
RX   PubMed=3458526;
RA   Ohyashiki K., Ohyashiki J.H., Sandberg A.A.;
RT   "Cytogenetic characterization of putative human myeloblastic leukemia
RT   cell lines (ML-1, -2, and -3): origin of the cells.";
RL   Cancer Res. 46:3642-3647(1986).
//
RX   PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid
RT   phosphatase.";
RL   Leuk. Res. 9:537-548(1985).
//
RX   PubMed=6091813; DOI=10.1182/blood.V64.5.1059.1059;
RA   Palumbo A., Minowada J., Erikson J., Croce C.M., Rovera G.;
RT   "Lineage infidelity of a human myelogenous leukemia cell line.";
RL   Blood 64:1059-1063(1984).
//
RX   PubMed=14671638; DOI=10.1038/sj.leu.2403236;
RA   Drexler H.G., Quentmeier H., MacLeod R.A.F.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   MLL gene alterations.";
RL   Leukemia 18:227-232(2004).
//
RX   PubMed=15843827; DOI=10.1038/sj.leu.2403749;
RA   Andersson A., Eden P., Lindgren D., Nilsson J., Lassen C., Heldrup J.,
RA   Fontes M., Borg A., Mitelman F., Johansson B., Hoglund M.,
RA   Fioretos T.;
RT   "Gene expression profiling of leukemic cell lines reveals conserved
RT   molecular signatures among subtypes with specific genetic
RT   aberrations.";
RL   Leukemia 19:1042-1050(2005).
//
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).
//
RX   PubMed=16969076; DOI=10.4161/cbt.5.8.3251;
RA   Edkins S., O'Meara S., Parker A., Stevens C., Reis M., Jones S.,
RA   Greenman C.D., Davies H., Dalgliesh G.L., Forbes S., Hunter C., Smith R.,
RA   Stephens P.J., Goldstraw P., Nicholson A., Chan T.-L., Velculescu V.E.,
RA   Yuen S.T., Leung S.Y., Stratton M.R., Futreal P.A.;
RT   "Recurrent KRAS codon 146 mutations in human colorectal cancer.";
RL   Cancer Biol. Ther. 5:928-932(2006).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//